Knight Therapeutics Statistics

Total Valuation

Knight Therapeutics has a market cap or net worth of CAD 569.50 million. The enterprise value is 466.31 million.

Market Cap	569.50M
Enterprise Value	466.31M

Important Dates

The next estimated earnings date is Friday, November 8, 2024.

Earnings Date	Nov 8, 2024
Ex-Dividend Date	n/a

Share Statistics

Knight Therapeutics has 100.98 million shares outstanding. The number of shares has decreased by -7.80% in one year.

Shares Outstanding	100.98M
Shares Change (YoY)	-7.80%
Shares Change (QoQ)	+0.15%
Owned by Insiders (%)	1.76%
Owned by Institutions (%)	24.72%
Float	86.23M

Valuation Ratios

PE Ratio	n/a
Forward PE	87.44
PS Ratio	1.72
PB Ratio	0.75
P/FCF Ratio	9.39
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.04, with an EV/FCF ratio of 7.69.

EV / Earnings	-21.97
EV / Sales	1.38
EV / EBITDA	8.04
EV / EBIT	58.28
EV / FCF	7.69

Financial Position

The company has a current ratio of 3.41, with a Debt / Equity ratio of 0.08.

Current Ratio	3.41
Quick Ratio	2.38
Debt / Equity	0.08
Debt / EBITDA	1.00
Debt / FCF	0.96
Interest Coverage	0.69

Financial Efficiency

Return on equity (ROE) is -2.70% and return on invested capital (ROIC) is 0.59%.

Return on Equity (ROE)	-2.70%
Return on Assets (ROA)	0.51%
Return on Capital (ROIC)	0.59%
Revenue Per Employee	466,033
Profits Per Employee	-29,277
Employee Count	725
Asset Turnover	0.34
Inventory Turnover	1.72

Taxes

Income Tax	-6.74M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +26.28% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+26.28%
50-Day Moving Average	5.78
200-Day Moving Average	5.68
Relative Strength Index (RSI)	46.60
Average Volume (20 Days)	61,015

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Knight Therapeutics had revenue of CAD 337.87 million and -21.23 million in losses. Loss per share was -0.21.

Revenue	337.87M
Gross Profit	163.43M
Operating Income	8.00M
Pretax Income	-23.69M
Net Income	-21.23M
EBITDA	55.40M
EBIT	8.00M
Loss Per Share	-0.21

Full Income Statement

Balance Sheet

The company has 157.47 million in cash and 58.11 million in debt, giving a net cash position of 103.19 million or 1.02 per share.

Cash & Cash Equivalents	157.47M
Total Debt	58.11M
Net Cash	103.19M
Net Cash Per Share	1.02
Equity (Book Value)	762.80M
Book Value Per Share	7.53
Working Capital	254.78M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 62.90 million and capital expenditures -2.26 million, giving a free cash flow of 60.64 million.

Operating Cash Flow	62.90M
Capital Expenditures	-2.26M
Free Cash Flow	60.64M
FCF Per Share	0.60

Full Cash Flow Statement

Margins

Gross margin is 48.37%, with operating and profit margins of 2.37% and -6.28%.

Gross Margin	48.37%
Operating Margin	2.37%
Pretax Margin	-7.01%
Profit Margin	-6.28%
EBITDA Margin	16.40%
EBIT Margin	2.37%
FCF Margin	17.95%

Dividends & Yields

Knight Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	7.80%
Shareholder Yield	7.80%
Earnings Yield	-3.65%
FCF Yield	10.65%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Knight Therapeutics has an Altman Z-Score of 2.69 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.69
Piotroski F-Score	6